These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28376406)

  • 1. Availability of dopamine transporters in heroin-dependent subjects: A
    Xu S; Liu Y; Li Y; Deng Y; Yuan J; Lv R; Wang Y; Zhang G; Guo Z; Fu D; Zeng H; Han M; Liu X
    Psychiatry Res Neuroimaging; 2017 May; 263():121-126. PubMed ID: 28376406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism.
    Masilamoni G; Votaw J; Howell L; Villalba RM; Goodman M; Voll RJ; Stehouwer J; Wichmann T; Smith Y
    Exp Neurol; 2010 Dec; 226(2):265-73. PubMed ID: 20832405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters.
    Goodman MM; Kilts CD; Keil R; Shi B; Martarello L; Xing D; Votaw J; Ely TD; Lambert P; Owens MJ; Camp VM; Malveaux E; Hoffman JM
    Nucl Med Biol; 2000 Jan; 27(1):1-12. PubMed ID: 10755640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and Biological Evaluation of [
    Cao S; Tang J; Liu C; Fang Y; Ji L; Xu Y; Chen Z
    Mol Imaging Biol; 2021 Oct; 23(5):733-744. PubMed ID: 33851345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT.
    Davis MR; Votaw JR; Bremner JD; Byas-Smith MG; Faber TL; Voll RJ; Hoffman JM; Grafton ST; Kilts CD; Goodman MM
    J Nucl Med; 2003 Jun; 44(6):855-61. PubMed ID: 12791810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements.
    Zoghbi SS; Shetty HU; Ichise M; Fujita M; Imaizumi M; Liow JS; Shah J; Musachio JL; Pike VW; Innis RB
    J Nucl Med; 2006 Mar; 47(3):520-7. PubMed ID: 16513622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of dopamine transporter density with [18F]FECNT PET in healthy humans.
    Nye JA; Votaw JR; Bremner JD; Davis MR; Voll RJ; Camp VM; Goodman MM
    Nucl Med Biol; 2014 Mar; 41(3):217-22. PubMed ID: 24533985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Difficulties in dopamine transporter radioligand PET analysis: the example of LBT-999 using [18F] and [11C] labelling Part I: PET studies.
    Saba W; Peyronneau MA; Dollé F; Goutal S; Bottlaender M; Valette H
    Nucl Med Biol; 2012 Feb; 39(2):227-33. PubMed ID: 22033025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of striatal dopamine transporter levels in chronic heroin-dependent and methamphetamine-dependent subjects.
    Yuan J; Liu XD; Han M; Lv RB; Wang YK; Zhang GM; Li Y
    Addict Biol; 2017 Jan; 22(1):229-234. PubMed ID: 26040446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users.
    Shi J; Zhao LY; Copersino ML; Fang YX; Chen Y; Tian J; Deng Y; Shuai Y; Jin J; Lu L
    Eur J Pharmacol; 2008 Jan; 579(1-3):160-6. PubMed ID: 17977528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of novel halo and tosyloxy nortropane derivatives as efficient precursors for the one-step synthesis of the dopamine transporter PET ligand [(18)F]FECNT.
    Pijarowska-Kruszyna J; Jaron AW; Kachniarz A; Kasprzak K; Kowalska A; Malkowski B; Demphel S; Dollé F; Mikolajczak R
    J Labelled Comp Radiopharm; 2014 Mar; 57(3):148-57. PubMed ID: 24497079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semi-automated preparation of the dopamine transporter ligand [(18)F]FECNT for human PET imaging studies.
    Voll RJ; McConathy J; Waldrep MS; Crowe RJ; Goodman MM
    Appl Radiat Isot; 2005 Sep; 63(3):353-61. PubMed ID: 15985372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients.
    Zaaijer ER; van Dijk L; de Bruin K; Goudriaan AE; Lammers LA; Koeter MW; van den Brink W; Booij J
    Psychopharmacology (Berl); 2015 Jul; 232(14):2597-607. PubMed ID: 25757673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.
    Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
    J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I.
    Sasaki T; Ito H; Kimura Y; Arakawa R; Takano H; Seki C; Kodaka F; Fujie S; Takahata K; Nogami T; Suzuki M; Fujiwara H; Takahashi H; Nakao R; Fukumura T; Varrone A; Halldin C; Nishikawa T; Suhara T
    J Nucl Med; 2012 Jul; 53(7):1065-73. PubMed ID: 22689927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prenatal stress induces increased striatal dopamine transporter binding in adult nonhuman primates.
    Converse AK; Moore CF; Moirano JM; Ahlers EO; Larson JA; Engle JW; Barnhart TE; Murali D; Christian BT; DeJesus OT; Holden JE; Nickles RJ; Schneider ML
    Biol Psychiatry; 2013 Oct; 74(7):502-10. PubMed ID: 23726316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET imaging of dopamine transporters with [(18)F]FE-PE2I: Effects of anti-Parkinsonian drugs.
    Bang JI; Jung IS; Song YS; Park HS; Moon BS; Lee BC; Kim SE
    Nucl Med Biol; 2016 Feb; 43(2):158-64. PubMed ID: 26872440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal changes of dopamine transporters in heroin users during abstinence.
    Xu S; Liu Y; Li Y; Deng Y; Huang Y; Yuan J; Lv R; Wang Y; Zhang G; Guo Z; Han M; Liu X; Fu D
    Psychopharmacology (Berl); 2015 Sep; 232(18):3391-401. PubMed ID: 26096461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET.
    Appel L; Bergström M; Buus Lassen J; Långström B
    Eur Neuropsychopharmacol; 2014 Feb; 24(2):251-61. PubMed ID: 24239329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine transporter availability in heroin-dependent subjects and controls: longitudinal changes during abstinence and the effects of Jitai tablets treatment.
    Liu Y; Han M; Liu X; Deng Y; Li Y; Yuan J; Lv R; Wang Y; Zhang G; Gao J
    Psychopharmacology (Berl); 2013 Nov; 230(2):235-44. PubMed ID: 23715641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.